Related Experiment Video
Updated: Apr 27, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells
Nirmita J Patel1, Rajesh Karuturi, Rami A Al-Horani
1Hunter Holmes McGuire VA Medical Center, Richmond, Virginia 23249, United States.
Abstract:
Selective targeting of cancer stem-like cells (CSCs) is a paradigm-shifting approach. We hypothesized that CSCs can be targeted by interfering with functions of sulfated glycosaminoglycans, which play key roles in cancer cell growth, invasion and metastasis. We developed a tandem, dual screen strategy involving (1) assessing inhibition of monolayer versus spheroid growth and (2) assessing inhibition of primary versus secondary spheroid growth to identify G2.2, a unique sulfated nonsaccharide GAG mimetic (NSGM) from a focused library of 53 molecules, as a selective inhibitor of colon CSCs. The NSGM down-regulated several CSC markers through regulation of gene transcription, while closely related, inactive NSGMs G1.4 and G4.1 demonstrated no such changes. G2.2's effects on CSCs were mediated, in part, through induction of apoptosis and inhibition of self-renewal factors. Overall, this work presents the proof-of-principle that CSCs can be selectively targeted through novel NSGMs, which are likely to advance fundamental understanding on CSCs while also aiding development of novel therapeutic agents.
Insights
Researchers identified G2.2, a novel sulfated nonsaccharide glycosaminoglycan mimetic (NSGM), as a selective inhibitor of colon cancer stem-like cells (CSCs). This discovery offers a new strategy for targeting CSCs and developing innovative cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cancer stem-like cells (CSCs) drive tumor growth, invasion, and metastasis.
- Targeting CSCs is a promising therapeutic strategy.
- Sulfated glycosaminoglycans (GAGs) are implicated in cancer progression.
Purpose of the Study:
- To identify novel agents that selectively target colon CSCs.
- To investigate the role of sulfated GAGs in CSC function.
- To develop a new therapeutic approach for colon cancer.
Main Methods:
- A tandem, dual screening strategy was employed.
- Inhibition of monolayer versus spheroid growth was assessed.
- Inhibition of primary versus secondary spheroid growth was evaluated.
- A library of 53 sulfated nonsaccharide GAG mimetics (NSGMs) was screened.
Main Results:
- G2.2, a unique NSGM, selectively inhibited colon CSCs.
- G2.2 down-regulated CSC markers via gene transcription regulation.
- Inactive NSGMs (G1.4, G4.1) showed no such effects.
- G2.2 induced apoptosis and inhibited self-renewal factors in CSCs.
Conclusions:
- CSCs can be selectively targeted using novel NSGMs.
- This study provides proof-of-principle for NSGM-based CSC targeting.
- The findings may advance understanding of CSC biology and aid therapeutic development.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
01:19Mesenchymal Stem Cells